Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2014, Article ID 796510, 16 pages
http://dx.doi.org/10.1155/2014/796510
Review Article

Alendronate versus Raloxifene for Postmenopausal Women: A Meta-Analysis of Seven Head-to-Head Randomized Controlled Trials

1Department of Orthopaedic Surgery, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009, China
2Department of Orthopaedic Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19014, USA
3Department of Epidemiology and Biostatistics, School of Public Health, Drexel University, Philadelphia, PA 19102, USA

Received 14 May 2013; Accepted 31 October 2013; Published 5 January 2014

Academic Editor: Faustino R. Pérez-López

Copyright © 2014 Tiao Lin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. NIfHaCE N.TA161, Osteoporosis—secondary prevention including strontium ranelate: guidance, 2008.
  2. U. A. Liberman, M. C. Hochberg, P. Geusens et al., “Hip and non-spine fracture risk reductions differ among antiresorptive agents: evidence from randomised controlled trials,” International Journal of Clinical Practice, vol. 60, no. 11, pp. 1394–1400, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. P. D. Miller and R. J. Derman, “What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis?” Osteoporosis International, vol. 21, no. 11, pp. 1793–1802, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. B. Ettinger, D. M. Black, B. H. Mitlak et al., “Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial,” The Journal of the American Medical Association, vol. 282, no. 7, pp. 637–645, 1999. View at Publisher · View at Google Scholar · View at Scopus
  5. D. B. Karpf, D. R. Shapiro, E. Seeman et al., “Prevention of nonvertebral fractures by alendronate: a meta-analysis,” The Journal of the American Medical Association, vol. 277, no. 14, pp. 1159–1164, 1997. View at Google Scholar · View at Scopus
  6. M. H. Murad, M. T. Drake, R. J. Mullan et al., “Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis,” Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 6, pp. 1871–1880, 2012. View at Publisher · View at Google Scholar
  7. A. Cranney, G. Guyatt, L. Griffith, G. Wells, P. Tugwell, and C. Rosen, “Meta-analyses of therapies for postmenopausal osteoporosis. IX: summary of meta-analyses of therapies for postmenopausal osteoporosis,” Endocrine Reviews, vol. 23, no. 4, pp. 570–578, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. C. MacLean, S. Newberry, M. Maglione et al., “Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis,” Annals of Internal Medicine, vol. 148, no. 3, pp. 197–213, 2008. View at Google Scholar · View at Scopus
  9. H. Raef, M. Al-Bugami, S. Balharith et al., “Updated recommendations for the diagnosis and management of osteoporosis: a local perspective,” Annals of Saudi Medicine, vol. 31, no. 2, pp. 111–128, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. F. Song, Y. K. Loke, T. Walsh, A. Glenny, A. J. Eastwood, and D. G. Altman, “Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews,” The British Medical Journal, vol. 338, Article ID b1147, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. L. Trinquart, A. Abbé, and P. Ravaud, “Impact of reporting bias in network meta-analysis of antidepressant placebo-controlled trials,” PLoS ONE, vol. 7, no. 4, Article ID e35219, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. N. Freemantle, C. Cooper, A. Diez-Perez et al., “Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis,” Osteoporosis International, vol. 24, no. 1, pp. 209–217, 2013. View at Publisher · View at Google Scholar
  13. R. B. Hopkins, R. Goeree, E. Pullenayegum et al., “The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women,” BMC Musculoskeletal Disorders, vol. 12, article 209, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. S. A. Foster, N. Shi, S. Curkendall et al., “Fractures in women treated with raloxifene or alendronate: a retrospective database analysis,” BMC Women's Health, vol. 13, article 15, 2013. View at Publisher · View at Google Scholar
  15. J. Iwamoto, Y. Sato, M. Uzawa, T. Takeda, and H. Matsumoto, “Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis,” Yonsei Medical Journal, vol. 49, no. 1, pp. 119–128, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. O. Johnell, W. H. Scheele, Y. Lu, J. Reginster, A. G. Need, and E. Seeman, “Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis,” Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 3, pp. 985–992, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Luckey, R. Kagan, S. Greenspan et al., “Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis,” Menopause, vol. 11, no. 4, pp. 405–415, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. E. Muscoso, N. Puglisi, C. Mamazza et al., “Antiresorption therapy and reduction in fracture susceptibility in the osteoporotic elderly patient: open study,” European Review for Medical and Pharmacological Sciences, vol. 8, no. 2, pp. 97–102, 2004. View at Google Scholar · View at Scopus
  19. R. R. Recker, D. Kendler, C. P. Recknor et al., “Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass,” Bone, vol. 40, no. 4, pp. 843–851, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. P. N. Sambrook, P. Geusens, C. Ribot et al., “Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (EFficacy of FOSAMAX versus EVISTA Comparison Trial) International,” Journal of Internal Medicine, vol. 255, no. 4, pp. 503–511, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. Z. Sanad, H. Ellakwa, and B. Desouky, “Comparison of alendronate and raloxifene in postmenopausal women with osteoporosis,” Climacteric, vol. 14, no. 3, pp. 369–377, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. J. P. T. Higgins, S. Green, and Cochrane Collaboration, Cochrane Handbook for Systematic Reviews of Interventions, Wiley-Blackwell, Chichester, UK, 2008.
  23. B. Baujat, C. Mahé, J. Pignon, and C. Hill, “A graphical method for exploring heterogeneity in meta-analyses: application to a meta-analysis of 65 trials,” Statistics in Medicine, vol. 21, no. 18, pp. 2641–2652, 2002. View at Publisher · View at Google Scholar · View at Scopus
  24. D. Atkins, D. Best, P. A. Briss et al., “Grading quality of evidence and strength of recommendations,” The British Medical Journal, vol. 328, no. 7454, pp. 1490–1494, 2004. View at Google Scholar · View at Scopus
  25. J. D. Adachi, S. Adami, P. M. Kulkarni, M. Wong, and J. L. Stock, “Similar proportions of women lose bone mineral density with raloxifene or alendronate treatment,” Journal of Clinical Densitometry, vol. 8, no. 3, pp. 273–277, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. R. Eastell, A. Rogers, X. Ni, and J. H. Krege, “Effects of raloxifene and alendronate on bone turnover as assessed by procollagen type I N-terminal propeptide,” Osteoporosis International, vol. 22, no. 6, pp. 1927–1934, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. B. Yanik, N. Bavbek, T. Yanǧk et al., “The effect of alendronate, risedronate, and raloxifene on renal functions, based on the cockcroft and gault method, in postmenopausal women,” Renal Failure, vol. 29, no. 4, pp. 471–476, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. M. R. Allen and D. B. Burr, “Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment,” Journal of Bone and Mineral Research, vol. 22, no. 11, pp. 1759–1765, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. J. A. Kanis, A. Oden, O. Johnell et al., “Uncertain future of trials in osteoporosis,” Osteoporosis International, vol. 13, no. 6, pp. 443–449, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. J. LeLorier, G. Grégoire, A. Benhaddad, J. Lapierre, and F. Derderian, “Discrepancies between meta-analyses and subsequent large randomized, controlled trials,” The New England Journal of Medicine, vol. 337, no. 8, pp. 536–542, 1997. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Giner, M. J. Rios, M. J. Montoya, M. A. Vázquez, C. Miranda, and R. Pérez-Cano, “Alendronate and raloxifene affect the osteoprotegerin/RANKL system in human osteoblast primary cultures from patients with osteoporosis and osteoarthritis,” European Journal of Pharmacology, vol. 650, no. 2-3, pp. 682–687, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Takeyama and H. Shinoda, “Pharmacological actions and pharmacokinetics of bisphosphonates,” Clinical Calcium, vol. 13, pp. 115–121, 2003. View at Google Scholar
  33. J. R. Rey, E. V. Cervino, M. L. Rentero, E. C. Crespo, A. O. Alvaro, and M. Casillas, “Raloxifene: mechanism of action, effects on bone tissue, and applicability in clinical traumatology practice,” Open Orthopaedics Journal, vol. 3, pp. 14–21, 2009. View at Publisher · View at Google Scholar
  34. M. R. Allen, K. Iwata, M. Sato, and D. B. Burr, “Raloxifene enhances vertebral mechanical properties independent of bone density,” Bone, vol. 39, no. 5, pp. 1130–1135, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. M. R. Allen and D. B. Burr, “Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: what we think we know and what we know that we don't know,” Bone, vol. 49, no. 1, pp. 56–65, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. S. R. Cummings, D. B. Karpf, F. Harris et al., “Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs,” The American Journal of Medicine, vol. 112, no. 4, pp. 281–289, 2002. View at Publisher · View at Google Scholar · View at Scopus
  37. Z. Li, M. P. Meredith, and M. S. Hoseyni, “A method to assess the proportion of treatment effect explained by a surrogate endpoint,” Statistics in Medicine, vol. 20, no. 21, pp. 3175–3188, 2001. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Sarkar, B. H. Mitlak, M. Wong, J. L. Stock, D. M. Black, and K. D. Harper, “Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy,” Journal of Bone and Mineral Research, vol. 17, no. 1, pp. 1–10, 2002. View at Google Scholar · View at Scopus
  39. N. B. Watts, C. Cooper, R. Lindsay et al., “Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk,” Journal of Clinical Densitometry, vol. 7, no. 3, pp. 255–261, 2004. View at Publisher · View at Google Scholar · View at Scopus
  40. M. R. Allen, K. Iwata, R. Phipps, and D. B. Burr, “Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate,” Bone, vol. 39, no. 4, pp. 872–879, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. J. R. Curtis, E. Delzell, L. Chen et al., “The relationship between bisphosphonate adherence and fracture: is it the behavior or the medication? Results from the placebo arm of the fracture intervention trial,” Journal of Bone and Mineral Research, vol. 26, no. 4, pp. 683–688, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. I. Imaz, P. Zegarra, J. González-Enríquez, B. Rubio, R. Alcazar, and J. M. Amate, “Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis,” Osteoporosis International, vol. 21, no. 11, pp. 1943–1951, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. A. R. Patrick, M. A. Brookhart, E. Losina et al., “The complex relation between bisphosphonate adherence and fracture reduction,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 7, pp. 3251–3259, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. E. Barrett-Connor, L. Mosca, P. Collins et al., “Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women,” The New England Journal of Medicine, vol. 355, no. 2, pp. 125–137, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. E. Barrett-Connor, J. A. Cauley, P. M. Kulkarni, A. Sashegyi, D. A. Cox, and M. J. Geiger, “Risk-benefit profile for raloxifene: 4-year data from the multiple outcomes of raloxifene evaluation (MORE) randomized trial,” Journal of Bone and Mineral Research, vol. 19, no. 8, pp. 1270–1275, 2004. View at Publisher · View at Google Scholar · View at Scopus
  46. H. Hansdóttir, “Raloxifene for older women: a review of the literature,” Clinical Interventions in Aging, vol. 3, no. 1, pp. 45–50, 2008. View at Google Scholar · View at Scopus
  47. P. D. Miller, G. Woodson, A. A. Licata et al., “Rechallenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptoms,” Clinical Therapeutics, vol. 22, no. 12, pp. 1433–1442, 2000. View at Publisher · View at Google Scholar · View at Scopus
  48. E. G. Pasion, S. K. Sivananthan, A. W. Kung et al., “Comparison of raloxifene and bisphosphonates based on adherence and treatment satisfaction in postmenopausal Asian women,” Journal of Bone and Mineral Metabolism, vol. 25, no. 2, pp. 105–113, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. J. D. Adachi, R. Y. Faraawi, M. F. J. O'Mahony et al., “Upper gastrointestinal tolerability of alendronate sodium monohydrate 10 mg once daily in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled, exploratory study,” Clinical Therapeutics, vol. 31, no. 8, pp. 1747–1753, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. B. Ettinger, A. Pressman, and J. Schein, “Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis,” The American Journal of Managed Care, vol. 4, no. 10, pp. 1377–1382, 1998. View at Google Scholar · View at Scopus